According to a research report published Thursday, J.P. Morgan has initiated GenMark Diagnostics GNMK with an Overweight rating and $8 PT.
In the report, J.P. Morgan said, "With an experienced management team commercializing an attractive technology (confirmed by our proprietary lab survey, discussed within) in a high-growth, high-value industry, GenMark is well positioned, in our view, to grow its installed base, broaden the offered test menu, and prepare for the late 2013 launch of its next-generation system."
GenMark Diagnostics closed Wednesday at $5.37.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in